The art and science of running a successful pharmaceutical company.
December 1, 2008
By:
Ron Feemster
We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond
|
November 13, 2008
By:
Jeffrey M. Sandman
Significant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole?
|
November 1, 2008
By:
Joanna Breitstein
Some say it's just another pharma facing its patent cliff. But others say this company's got it worse. With new CEO John Lechleiter in charge, can Lilly find its way back from the edge?
|
November 1, 2008
A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri
|
November 1, 2008
By:
Patrick Clinton
The former health secretary offers a reality check on healthcare reform—and what to expect from the pols in '09
|
October 1, 2008
By:
Walter Armstrong
Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?
|
October 1, 2008
Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.
|
October 1, 2008
By:
Joanna Breitstein
Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
